Mycobacterium tuberculosis
Mycobacterium tuberculosis (M. tb) is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. First discovered in 1882 by Robert Koch, "M. tuberculosis" has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid. This coating makes the cells impervious to Gram staining, and as a result, "M. tuberculosis" can appear weakly Gram-positive. Acid-fast stains such as Ziehl–Neelsen, or fluorescent stains such as auramine are used instead to identify "M. tuberculosis" with a microscope. The physiology of "M. tuberculosis" is highly aerobic and  requires high levels of oxygen. Primarily a pathogen of the mammalian respiratory system, it infects the lungs. The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction. The "M. tuberculosis" genome was sequenced in 1998. Microbiology. M. tuberculosis was found in a complex in 2019 that has at least 9 members: "M. tuberculosis" "sensu stricto", "M. africanum, M. canetti, M. bovis, M. caprae, M. microti", "M. pinnipedii", "M. mungi," and "M. orygis". It requires oxygen to grow, it is debated whether it produces spores, and is nonmotile. "M. tuberculosis  divides every 18–24 hours. This is extremely slow compared with other bacteria, which tend to have division times measured in minutes (Escherichia coli" can divide roughly every 20 minutes). It is a small bacillus that can withstand weak disinfectants and can survive in a dry state for weeks. Its unusual cell wall is rich in lipids such as mycolic acid, is likely responsible for its resistance to desiccation and is a key virulence factor. Microscopy. Other bacteria are commonly identified with a microscope by staining them with Gram stain. However, the mycolic acid in the cell wall of "M. tuberculosis  does not absorb the stain. Instead, acid-fast stains such as Ziehl–Neelsen stain, or fluorescent stains such as auramine are used. Cells are curved rod-shaped and are often seen wrapped together, due to the presence of fatty acids in the cell wall that stick together. This appearance is referred to as cording, like strands of cord that make up a rope. M. tuberculosis" is characterized in tissue by caseating granulomas containing Langhans giant cells, which have a "horseshoe" pattern of nuclei. Culture. "M. tuberculosis" can be grown in the laboratory. Compared to other commonly studied bacteria, "M. tuberculosis  has a remarkably slow growth rate, doubling roughly once per day. Commonly used media include liquids such as Middlebrook 7H9 or 7H12, egg-based solid media such as Lowenstein-Jensen, and solid agar-based such as Middlebrook 7H11 or 7H10. Visible colonies require several weeks to grow on agar plates. It is distinguished from other mycobacteria by its production of catalase and niacin. Other tests to confirm its identity include gene probes and MALDI-TOF. Pathophysiology. Humans are the only known reservoirs of M. tuberculosis". A misconception is that "M. tuberculosis" can be spread by shaking hands, making contact with  toilet seats, sharing food or drink, or sharing toothbrushes. However, major spread is through air droplets originating from a person who has the disease either coughing, sneezing, speaking, or singing. When in the lungs, "M. tuberculosis" is phagocytosed by alveolar macrophages, but they are unable to kill and digest the bacterium. Its cell wall inhibits the fusion of the phagosome with the lysosome, which contains a host of antibacterial factors. Specifically, "M. tuberculosis" blocks the bridging molecule, early endosomal autoantigen 1 (EEA1); however, this blockade does not prevent fusion of vesicles filled with nutrients. In addition, production of the diterpene  isotuberculosinol prevents maturation of the phagosome. The bacteria also evades macrophage-killing by neutralizing reactive nitrogen intermediates. More recently, "M. tuberculosis" has been shown to secrete and cover itself in 1-tuberculosinyladenosine (1-TbAd), a special nucleoside that acts as an antacid, allowing it to neutralize pH and induce swelling in lysosomes. In "M. tuberculosis" infections, PPM1A levels were found to be upregulated, and this, in turn, would impact the normal apoptotic response of macrophages to clear pathogens, as PPM1A is involved in the intrinsic and extrinsic apoptotic pathways. Hence, when PPM1A levels were increased, the expression of it inhibits  the two apoptotic pathways. With kinome analysis, the JNK/AP-1 signalling pathway was found to be a downstream effector that PPM1A has a part to play in, and the apoptotic pathway in macrophages are controlled in this manner. As a result of having apoptosis being suppressed, it provides "M. tuberculosis" with a safe replicative niche, and so the bacteria are able to maintain a latent state for a prolonged time. Granulomas, organized aggregates of immune cells, are a hallmark feature of tuberculosis infection. Granulomas play dual roles during infection: they regulate the immune response and minimize tissue damage, but also  can aid in the expansion of infection. The ability to construct "M. tuberculosis" mutants and test individual gene products for specific functions has significantly advanced the understanding of its pathogenesis and virulence factors. Many secreted and exported proteins are known to be important in pathogenesis. For example, one such virulence factor is cord factor (trehalose dimycolate), which serves to increase survival within its host. Resistant strains of "M. tuberculosis" have developed resistance to more than one TB drug, due to mutations in their genes. In addition, pre-existing first-line TB drugs such as rifampicin and streptomycin have decreased efficiency  in clearing intracellular "M. tuberculosis" due not being able to effectively penetrate the macrophage niche JNK plays a key role in the control of apoptotic pathways—intrinsic and extrinsic. In addition, it is also found to be a substrate of PPM1A activity, hence the phosphorylation of JNK would cause apoptosis to occur. Since PPM1A levels are elevated during "M. tuberculosis" infections, by inhibiting the PPM1A signalling pathways, it could potentially be a therapeutic method to kill "M. tuberculosis"-infected macrophages by restoring its normal apoptotic function in defence of pathogens. By targeting the PPM1A-JNK signalling axis pathway, then, it could  eliminate "M. tuberculosis"-infected macrophages. The ability to restore macrophage apoptosis to "M. tuberculosis"-infected ones could improve the current tuberculosis chemotherapy treatment, as TB drugs can gain better access to the bacteria in the niche. thus decreasing the treatment times for "M. tuberculosis" infections. Symptoms of "M. tuberculosis" include coughing that lasts for more than three weeks, hemoptysis, chest pain when breathing or coughing, weight loss, fatigue, fever, night sweats, chills, and loss of appetite. "M. tuberculosis" also has the potential of spreading to other parts of the body. This can cause blood in urine if the kidneys are affected, and  back pain if the spine is affected. Strain variation. Typing of strains is useful in the investigation of tuberculosis outbreaks, because it gives the investigator evidence for or against transmission from person to person. Consider the situation where person A has tuberculosis and believes he acquired it from person B. If the bacteria isolated from each person belong to different types, then transmission from B to A is definitively disproven; however, if the bacteria are the same strain, then this supports (but does not definitively prove) the hypothesis that B infected A. Until the early 2000s, "M. tuberculosis" strains were  typed by pulsed field gel electrophoresis. This has now been superseded by variable numbers of tandem repeats (VNTR), which is technically easier to perform and allows better discrimination between strains. This method makes use of the presence of repeated DNA sequences within the "M. tuberculosis" genome. Three generations of VNTR typing for "M. tuberculosis" are noted. The first scheme, called exact tandem repeat, used only five loci, but the resolution afforded by these five loci was not as good as PFGE. The second scheme, called mycobacterial interspersed repetitive unit, had discrimination as good as PFGE. The third generation (mycobacterial interspersed  repetitive unit – 2) added a further nine loci to bring the total to 24. This provides a degree of resolution greater than PFGE and is currently the standard for typing "M. tuberculosis". However, with regard to archaeological remains, additional evidence may be required because of possible contamination from related soil bacteria. Antibiotic resistance in "M. tuberculosis" typically occurs due to either the accumulation of mutations in the genes targeted by the antibiotic or a change in titration of the drug. "M. tuberculosis" is considered to be multidrug-resistant (MDR TB) if it has developed drug resistance to both rifampicin and  isoniazid, which are the most important antibiotics used in treatment. Additionally, extensively drug-resistant "M. tuberculosis" (XDR TB) is characterized by resistance to both isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). Genome. The genome of the H37Rv strain was published in 1998. Its size is 4 million base pairs, with 3,959 genes; 40% of these genes have had their function characterized, with possible function postulated for another 44%. Within the genome are also six pseudogenes. The genome contains 250 genes involved in fatty acid metabolism, with  39 of these involved in the polyketide metabolism generating the waxy coat. Such large numbers of conserved genes show the evolutionary importance of the waxy coat to pathogen survival. Furthermore, experimental studies have since validated the importance of a lipid metabolism for" M. tuberculosis", consisting entirely of host-derived lipids such as fats and cholesterol. Bacteria isolated from the lungs of infected mice were shown to preferentially use fatty acids over carbohydrate substrates. "M. tuberculosis" can also grow on the lipid cholesterol as a sole source of carbon, and genes involved in the cholesterol use pathway(s) have been validated as  important during various stages of the infection lifecycle of "M. tuberculosis", especially during the chronic phase of infection when other nutrients are likely not available. About 10% of the coding capacity is taken up by the "PE"/"PPE" gene families that encode acidic, glycine-rich proteins. These proteins have a conserved N-terminal motif, deletion of which impairs growth in macrophages and granulomas. Nine noncoding sRNAs have been characterised in "M. tuberculosis", with a further 56 predicted in a bioinformatics screen. In 2013, a study on the genome of several sensitive, ultraresistant, and multiresistant "M. tuberculosis" strains was made to study  antibiotic resistance mechanisms. Results reveal new relationships and drug resistance genes not previously associated and suggest some genes and intergenic regions associated with drug resistance may be involved in the resistance to more than one drug. Noteworthy is the role of the intergenic regions in the development of this resistance, and most of the genes proposed in this study to be responsible for drug resistance have an essential role in the development of "M. tuberculosis". Evolution. The "M. tuberculosis" complex evolved in Africa and most probably in the Horn of Africa. In addition to "M. tuberculosis", the "M. tuberculosis" complex  (MTBC) has a number of members infecting various animal species, these include "M. africanum", "M. bovis" (Dassie's bacillus), "M. caprae", "M. microti", "M. mungi, M. orygis", and "M. pinnipedii". This group may also include the "M. canettii" clade. These animal strains of MTBC do not strictly deserve species status, as they are all closely related and embedded in the "M. tuberculosis" phylogeny, but for historic reasons, they currently hold species status. The "M. canettii" clade – which includes "M. prototuberculosis" – is a group of smooth-colony "Mycobacterium" species. Unlike the established members of the "M. tuberculosis" group, they undergo recombination  with other species. The majority of the known strains of this group have been isolated from the Horn of Africa. The ancestor of "M. tuberculosis" appears to be "M. canettii", first described in 1969. The established members of the "M. tuberculosis" complex are all clonal in their spread. The main human-infecting species have been classified into seven lineages. Translating these lineages into the terminology used for spoligotyping, a very crude genotyping methodology, lineage 1 contains the East African-Indian (EAI), the Manila family of strains and some Manu (Indian) strains; lineage 2 is the Beijing group; lineage 3 includes  the Central Asian (CAS) strains; lineage 4 includes the Ghana and Haarlem (H/T), Latin America-Mediterranean (LAM) and X strains; types 5 and 6 correspond to "M. africanum" and are observed predominantly and at high frequencies in West Africa. A seventh type has been isolated from the Horn of Africa. The other species of this complex belong to a number of spoligotypes and do not normally infect humans. Lineages 2, 3 and 4 all share a unique deletion event (tbD1) and thus form a monophyletic group. Types 5 and 6 are closely related to the animal strains of MTBC , which do not normally infect humans. Lineage 3 has been divided into two clades: CAS-Kili (found in Tanzania) and CAS-Delhi (found in India and Saudi Arabia). Lineage 4 is also known as the Euro-American lineage. Subtypes within this type include Latin American Mediterranean, Uganda I, Uganda II, Haarlem, X, and Congo. A much cited study reported that "M. tuberculosis" has co-evolved with human populations, and that the most recent common ancestor of the "M. tuberculosis" complex evolved between 40,000 and 70,000 years ago. However, a later study that included genome sequences from "M. tuberculosis" complex members  extracted from three 1,000-year-old Peruvian mummies, came to quite different conclusions. If the most recent common ancestor of the "M. tuberculosis" complex were 40,000 to 70,000 years old, this would necessitate an evolutionary rate much lower than any estimates produced by genomic analyses of heterochronous samples. An analysis of over 3000 strains of "M. bovis" from 35 countries suggested an Africa origin for this species. Co-evolution with modern humans. There are currently two narratives existing in parallel regarding the age of MTBC and how it has spread and co-evolved with humans through time. One study compared  the "M. tuberculosis" phylogeny to a human mitochondrial genome phylogeny and interpreted these as being highly similar. Based on this, the study suggested that "M. tuberculosis", like humans, evolved in Africa and subsequently spread with anatomically modern humans out of Africa across the world. By calibrating the mutation rate of M. tuberculosis to match this narrative, the study suggested that MTBC evolved 40,000–70,000 years ago. Applying this time scale, the study found that the "M. tuberculosis" effective population size expanded during the Neolithic Demographic Transition (around 10,000 years ago) and suggested that "M. tuberculosis" was able to adapt to changing  human populations and that the historical success of this pathogen was driven at least in part by dramatic increases in human host population density. It has also been demonstrated that after emigrating from one continent to another, a human host's region of origin is predictive of which TB lineage they carry, which could reflect either a stable association between host populations and specific "M. tuberculosis" lineages and/or social interactions that are shaped by shared cultural and geographic histories. Regarding the congruence between human and "M. tuberculosis" phylogenies, a study relying on "M. tuberculosis" and human Y chromosome DNA sequences  to formally assess the correlation between them, concluded that they are not congruent. Also, a more recent study which included genome sequences from "M. tuberculosis" complex members extracted from three 1,000-year-old Peruvian mummies, estimated that the most recent common ancestor of the "M. tuberculosis" complex lived only 4,000 – 6,000 years ago. The "M. tuberculosis" evolutionary rate estimated by the Bos et al. study is also supported by a study on Lineage 4 relying on genomic aDNA sequences from Hungarian mummies more than 200 years old. In total, the evidence thus favors this more recent estimate of the age  of the MTBC most recent common ancestor, and thus that the global evolution and dispersal of "M. tuberculosis" has occurred over the last 4,000–6,000 years. Among the seven recognized lineages of "M. tuberculosis", only two are truly global in their distribution: Lineages 2 and 4. Among these, Lineage 4 is the most well dispersed, and almost totally dominates in the Americas. Lineage 4 was shown to have evolved in or in the vicinity of Europe, and to have spread globally with Europeans starting around the 13th century. This study also found that Lineage 4 tuberculosis spread to the Americas shortly  after the European discovery of the continent in 1492, and suggests that this represented the first introduction of human TB on the continent (although animal strains have been found in human remains predating Columbus. Similarly, Lineage 4 was found to have spread from Europe to Africa during the Age of Discovery, starting in the early 15th century. It has been suggested that ancestral mycobacteria may have infected early hominids in East Africa as early as three million years ago. DNA fragments from "M. tuberculosis" and tuberculosis disease indications were present in human bodies dating from 9250–8160 years ago found at  Atlit-Yam in the Levant. Antibiotic resistance (ABR). "M. tuberculosis" is a clonal organism and does not exchange DNA via horizontal gene transfer. Despite an additionally slow evolution rate, the emergence and spread of antibiotic resistance in "M. tuberculosis" poses an increasing threat to global public health. In 2019, the WHO reported the estimated incidence of antibiotic resistant TB to be 3.4% in new cases, and 18% in previously treated cases. Geographical discrepancies exist in the incidence rates of drug-resistant TB. Countries facing the highest rates of ABR TB China, India, Russia, and South Africa. Recent trends reveal an  increase in drug-resistant cases in a number of regions, with Papua New Guinea, Singapore, and Australia undergoing significant increases. Multidrug-resistant Tuberculosis (MDR-TB) is characterised by resistance to at least the two front-line drugs isoniazid and rifampin. MDR is associated with a relatively poor treatment success rate of 52%. Isoniazid and rifampin resistance are tightly linked, with 78% of the reported rifampin-resistant TB cases in 2019 being resistant to isoniazid as well. Rifampin-resistance is primarily due to resistance-conferring mutations in the rifampin-resistance determining region (RRDR) within the rpoB gene. The most frequently observed  mutations of the codons in RRDR are 531, 526 and 516. However, alternative more elusive resistance-conferring mutations have been detected. Isoniazid function occurs through the inhibition of mycolic acid synthesis through the NADH-dependent enoyl-acyl carrier protein (ACP)-reductase. This is encoded by the "inhA" gene. As a result, isoniazid resistance is primarily due to mutations within inhA and the KatG gene or its promoter region - a catalase peroxidase which is required to activate Isoniazid. As MDR in "M. tuberculosis" becomes increasingly common, the emergence of pre-extensively drug resistant (pre-XDR) and extensively drug resistant (XDR-) TB threatens  to exasperate the public health crisis. XDR-TB is characterised by resistance to both rifampin and Isoniazid, as well second-line fluoroquinolones and at least one additional front-line drug. Thus, the development of alternative therapeutic measures is of utmost priority. An intrinsic contributor to the antibiotic resistant nature of "M. tuberculosis" is its unique cell wall. Saturated with long-chain fatty acids or mycolic acids, the mycobacterial cell presents a robust, relatively insoluble barrier. This has led to its synthesis being the target of many antibiotics - such as Isoniazid. However, resistance has emerged to the majority of them. A  novel, promising therapeutic target is mycobacterial membrane protein large 3 (MmpL3). The mycobacterial membrane protein large (MmpL) proteins are transmembrane proteins which play a key role in the synthesis of the cell wall and the transport of the associated lipids. Of these, MmpL3 is essential; knock-out of which has been shown to be bactericidal. Due to its essential nature, MmpL3 inhibitors show promise as alternative therapeutic measures in the age of antibiotic resistance. Inhibition of MmpL3 function showed an inability to transport trehalose monomycolate - an essential cell wall lipid - across the plasma membrane. The recently reported structure of MmpL3  revealed resistance-conferring mutations to associate primarily with the transmembrane domain. Although resistance to pre-clinical MmpL3 inhibitors has been detected, analysis of the wide-spread mutational landscape revealed a low level of environmental resistance. This suggests that MmpL3 inhibitors currently undergoing clinical trials would face little resistance if made available. Additionally, the ability of many MmpL3 inhibitors to work synergistically with other antitubercular drugs presents a ray of hope in combatting the TB crisis. Host genetics. The nature of the host-pathogen interaction between humans and "M. tuberculosis" is considered to have a genetic component. A group of rare  disorders called Mendelian susceptibility to mycobacterial diseases was observed in a subset of individuals with a genetic defect that results in increased susceptibility to mycobacterial infection. Early case and twin studies have indicated that genetic components are important in host susceptibility to "M. tuberculosis". Recent genome-wide association studies (GWAS) have identified three genetic risk loci, including at positions 11p13 and 18q11. As is common in GWAS, the variants discovered have moderate effect sizes. DNA repair. As an intracellular pathogen, "M. tuberculosis" is exposed to a variety of DNA-damaging assaults, primarily from host-generated antimicrobial toxic radicals. Exposure to  reactive oxygen species and/or reactive nitrogen species causes different types of DNA damage including oxidation, depurination, methylation, and deamination that can give rise to single- and double-strand breaks (DSBs). DnaE2 polymerase is upregulated in "M. tuberculosis" by several DNA-damaging agents, as well as during infection of mice. Loss of this DNA polymerase reduces the virulence of "M. tuberculosis" in mice. DnaE2 is an error-prone DNA repair polymerase that appears to contribute to "M. tuberculosis" survival during infection. The two major pathways employed in repair of DSBs are homologous recombinational repair (HR) and nonhomologous end joining (NHEJ). Macrophage -internalized "M. tuberculosis" is able to persist if either of these pathways is defective, but is attenuated when both pathways are defective. This indicates that intracellular exposure of "M. tuberculosis" to reactive oxygen and/or reactive nitrogen species results in the formation of DSBs that are repaired by HR or NHEJ. However deficiency of DSB repair does not appear to impair "M. tuberculosis" virulence in animal models. History. "M. tuberculosis", then known as the "tubercle bacillus", was first described on 24 March 1882 by Robert Koch, who subsequently received the Nobel Prize in Physiology or Medicine for this discovery in 1905 ; the bacterium is also known as "Koch's bacillus". "M. tuberculosis" has existed throughout history, but the name has changed frequently over time. In 1720, though, the history of tuberculosis started to take shape into what is known of it today; as the physician Benjamin Marten described in his "A Theory of Consumption", tuberculosis may be caused by small living creatures transmitted through the air to other patients. Vaccine. The BCG vaccine (bacille Calmette-Guerin), which was derived from "M. bovis," while effective against childhood and severe forms of tuberculosis, has limited success in preventing the most common form of  the disease today, adult pulmonary tuberculosis. Because of this, it is primarily used in high tuberculosis incidence regions, and is not a recommended vaccine in the United States due to the low risk of infection. To receive this vaccine in the United States, an individual is required to go through a consultation process with an expert in M. tuberculosis and is only given to those who meet the specific criteria. The BCG, according to an article of the Kyodo News (April 14, 2020) titled "Tuberculosis vaccine drawing attention in fight against coronavirus" indicates a possible correlation between BCG vaccination, and  better immune response to the COVID-19.